Truist Securities Reiterates Buy on Iovance Biotherapeutics, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Asthika Goonewardene has reiterated a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $17.
July 11, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iovance Biotherapeutics has received a reiterated 'Buy' rating from Truist Securities, with a maintained price target of $17.
The reiterated 'Buy' rating from Truist Securities indicates a positive outlook for Iovance Biotherapeutics. The maintained price target of $17 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100